Journal
JOURNAL OF DERMATOLOGICAL SCIENCE
Volume 100, Issue 2, Pages 110-119Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.jdermsci.2020.08.013
Keywords
Malignant melanoma; matrin-3; Cell survive; Apoptosis; Cell cycle
Categories
Funding
- Japan Society for the Promotion of Science (JSPS) [15K09772, 18K08301]
- JSPS [25670400, 21770119]
- Grants-in-Aid for Scientific Research [25670400, 21770119, 18K08301] Funding Source: KAKEN
Ask authors/readers for more resources
Background: A previous study revealed that matrin-3 is an essential component in maintaining fibroblast growth factor 2 (FGF2)-mediated undifferentiation of neural stem cells (NSCs) using a proteomics approach. Malignant melanoma (MM) arises from melanocytes that originate from neural crest stem cells during development. Additionally, it has been reported that the expression of FGF2 is positively correlated with the progression of MM. Objective: We expected that matrin-3, as a downstream component of FGF2, might be associated with the aggressiveness or differentiation of MM. Methods: Matrin-3 expression was measured in human melanoma patient tissues and human MM cell lines. We analyzed the effect of matrin-3 siRNA on the proliferation of human MM cell lines and focused on cell cycle progression and apoptosis. We carried out in vivo xenograft tumor experiments by implanting A375 cells transfected with matrin-3 shRNA. Results: Matrin-3 was highly expressed in MM, and matrin-3 knockdown inhibited the proliferation of melanoma cellsin vivo and in vitro. Furthermore, we found that matrin-3 knockdown led to an accumulation of cells in the G1 phase and an increase in apoptotic cell number. Conclusion: Our results suggest that matrin-3 could be a new therapeutic target for the treatment of MM. (C) 2020 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available